The federal grant will fund TPN-101 studies aimed at helping people stay healthier and sharper as they age.
Aging has been treated as a slow, inevitable slide. But with a new project from California-based biotech Transposon Therapeutics, that story might be changing. The company has been awarded up to $22 million by the Advanced Research Projects Agency for Health (ARPA-H) to study its drug TPN-101 under the PROSPR program, which focuses on extending healthspan [1].
Dennis Podlesak, chairman and CEO of Transposon, said that the award presented a pivotal opportunity to advance TPN-101 into a novel therapeutic category targeting the root causes of age-related diseases.
“With no FDA-approved therapies to extend healthspan, we believe TPN-101 has the potential to be at the forefront with a first-in-class approach to preserving function, preventing long-term disease, and extending the years of healthy life,” he noted.
Unlike conventional medicines that treat one disease at a time, TPN-101 is designed to slow a biological process that drives aging itself. Think of it as addressing the root of the problem rather than the symptoms. Instead of waiting for frailty, cognitive decline or chronic disease to appear, the idea is to intervene earlier.
Andrew Brack, ARPA-H program manager and creator of the PROSPR program, explained that they “have known for years that non-infection related inflammation increases with age and is linked to poor aging outcomes.”
There is excitement about the use of antiretroviral treatments to promote healthy aging. This stems from recent reports suggesting that LINE-1 retrotransposons contribute to age-related inflammation.
For everyday people, this could mean a future where 70 doesn’t automatically feel like 90, where your body and mind keep pace with your ambitions, and where the end-of-life period can be compressed into a much shorter window.
TPN-101 targets something called LINE-1 reverse transcriptase, a mechanism in our DNA that can “copy and jump” around the genome. In young, healthy cells, these jumps are tightly controlled. However, as we age, LINE-1 activity goes haywire, triggering inflammation and contributing to age-related diseases, including Alzheimer’s and ALS.
If you imagine the cell as a well-run city, LINE-1 elements are like construction crews. In youth, they build responsibly. Over time, they start building in all the wrong places, causing traffic jams and structural problems. TPN-101 essentially acts as a city planner, slowing rogue crews down, keeping the infrastructure intact and keeping the city functional.
According to Transposon’s Chief Medical Officer, Dr Andrew Satlin, the program enables a thorough assessment of TPN-101’s potential to help individuals maintain their physical and mental health as they age. He noted that rather than addressing specific diseases individually, the treatment aims to slow the fundamental biological processes that drive aging.
Transposon isn’t working alone. The company will collaborate with several leading universities, including the University of Rochester, Brown University, the University of Connecticut, the University of Texas Medical Branch, the University of Texas Health and the University of Nebraska. Together, they will study whether TPN-101 can safely and effectively extend healthspan, a first step toward bringing longevity science out of theory and into everyday life.
Currently, TPN-101 is also in late-stage clinical trials for neurodegenerative diseases like progressive supranuclear palsy (PSP), ALS and Alzheimer’s disease, where similar cellular mechanisms are at play. By testing it in a broader aging context, Transposon could provide a window into slowing the underlying biology that drives multiple conditions at once.
No drug has yet been approved specifically to extend healthy years of life. That makes this project not just science, but a relevant change in how we think about aging. TPN-101 could represent a new class of therapies.